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Background. Several risk factors for patients treated with peri-
toneal dialysis (PD) have now been identified. These include age,
comorbid disease, nutritional status, loss of residual renal function
(RRF) and high peritoneal solute transport. This is not the same,
however, as knowing what actually happens to these patients,
particularly in the long-term. The purpose of this review was to
give as complete a description as is currently possible of the
long-term PD patient.
Methods. The literature was surveyed for publications that
provide longitudinal cohort data of either selected or unselected
patient groups. Detailed data from the Stoke PD Study is pre-
sented in the context of these studies. Three principle aspects of
what really happens to patients were considered: (1) death, both
cause and mode of death; (2) technique failure, with reference to
peritoneal function and how the cause of technique failure related
to patient survival; and (3) evolution of clinically relevant param-
eters of patients on PD, such as nutrition and peritoneal function.
Results. Sudden death and debilitation were the predominant
modes of death, with sepsis playing a contributory role. Debilita-
tion was important regardless of co-existent comorbid disease,
and time to death was not influenced by the mode of death.
Predominant causes for technique failure remain peritonitis and
ultrafiltration, the latter becoming more important with time on
treatment. Technical failure is associated with poorer survival,
particularly when due to multiple peritonitis or failure to cope
with treatment. Cox regression demonstrated that whereas low
albumin, loss of RRF and high solute transport predicted patient
death, only high solute transport predicted technique failure.
Longitudinal changes over the first five years of treatment in-
cluded loss of RRF, increasing solute transport and following an
initial improvement in nutritional state, a decline after two years.
Patients surviving long-term PD (at least five years, N 5 25) were
characterized by prolonged RRF, maintained nutrition and lower
solute transport in the medium term.
Conclusions. Several studies of long-term PD in the literature
now complement each other in providing a picture of what really
happens to PD patients. The links between loss of solute clear-
ance and poor peritoneal ultrafiltration combining to exacerbate
sudden or debilitated death and technique failure are emerging.
For PD to be successful as a long-term therapy, strategies that
maintain nutrition and preserve peritoneal membrane function
must be developed.
Despite the fact that continuous forms of peritoneal
dialysis (PD) have been in use for 20 years and that it is a
well established treatment in the medium-term [1–3], our
detailed understanding of what actually happens to patients
using this modality in the longer term is only now beginning
to develop. The 1980s were spent addressing the more
pressing problems of the technique, such as high peritonitis
rates, while at the same time those factors that determine
patient outcome as they relate to dialysis adequacy were
beginning to be defined for the hemodialysis population [4].
The 1990s have seen these concerns addressed within the
PD population, and we now have a far clearer idea of those
factors that predict good outcome in these patients [5–7].
However, this is not the same thing as knowing what
actually happens to these individuals, which is the focus of
the present review.
There are now several large cohort studies in the litera-
ture that provide information about what actually happens
to patients on PD in the medium to longer term, and these
are summarized in Table 1 [2, 3, 8–16]. These studies vary
in size, with the larger multicenter studies having the
advantage of patient numbers that can address comparative
survival (patient and technique) with hemodialysis [2, 3, 10,
13, 16], whereas the smaller or single center studies can
provide greater detail on nutrition, solute kinetics and
peritoneal membrane function [8, 9, 11, 12, 14, 15].
The Stoke Peritoneal Dialysis Study was set up in 1990
specifically to examine how peritoneal membrane function
is influenced by the treatment and its complications with
time on PD, and also to establish how it in turn influences
patient outcome. In addition, the study has taken a close
look at nutrition in these patients. Several important ob-
servations have already been made. These include clinical
evaluation of the peritoneal equilibration test [17], the
effect of comorbidity on appetite suppression [18], interac-
tion of peritoneal function with varying comorbidities and
patient survival [19], longitudinal changes in peritoneal
function and the influence of peritonitis [20], and the
relationship of solute transport to patient survival [7].
There are now sufficient data to provide a detailed descrip-
tion of what actually happens to PD patients during the first
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five years of treatment, and this is presented below in the
context of a review of the existing literature.
Three principle areas need to be considered in order to
provide a complete picture of what actually happens to PD
patients: (1) death, (2) transfer to hemodialysis after tech-
nique failure, and (3) the evolution of clinically relevant
parameters that change with time on PD, such as nutrition
and peritoneal membrane function. Before the latter can
be interpreted, which will inevitably be shaped by patient
selection associated with treatment drop-out, a thorough
understanding of death and technical failure is required.
This review will deal with each of these areas in turn.
METHODS
Analysis of the literature
A literature search was conducted to identify publica-
tions that might provide relevant information concerning
long-term PD patients. Studies were included (Table 1) if
(1) they were published after 1990, (2) they represented a
prospective cohort of either selected or unselected patients,
and (3) that they contained significant data at five years or
more. In view of the tendency of authors to re-publish data
once patient numbers have increased, the review was
limited to one type of study per author group. During this
process a number of other important studies investigating
long-term PD patients were identified, and while not
strictly prospective cohort studies, they are discussed in the
text [21–23]. To facilitate the comparison between cohort
studies, five-year patient and technique survival rates were
derived from the published survival curves, as these were
not always available from the text or tables. As such, the
accuracy of these derivations are within a few percentage
points.
Where possible, the survival data reflect crude percent-
ages, although occasionally the data are only represented
when adjusted for risk factors (Table 2). Technical survival
was derived by considering a switch to hemodialysis as the
final event, treating death and transplantation as lost to
follow-up.






Maiorca et al 7 years 483 Multicenter 6 Italian Centers Comparative study with HD. Patient and technique survival.
1991 [2]
Rotellar et al 10 years 171 Single Center Patient and technique survival.
1991 [8]
Selgas et al 11 years 56 Single Center Selected patients on PD more than three years, solute clearance data.
1993 [9]
Lupo et al 10 years 1,990 Multicenter Italian Cooperative Dialysis Study Group (30 Centers). Patient and technique
survival.1994 [10]
Faller & Lamiere 7 years 23 Two Centers Selected patient group. Detailed data on solute clearance and membrane
function.1993 [9]
1994 [11]
Selgas et al 11 years 56 Single Center Selected patients on PD more than three years, membrane function data.
1994 [12]




5 years 22 Single Center Selected group of patients on treatment at least 5 years, from a cohort of 734.
Describes characteristics including membrane function.
1997 [14]
Abdel-Rahman et al 18 years 20 Single Center Retrospective analysis of 20 patients on PD more than 100 months from a
cohort of 165. Describes characteristics including age and dialysis
prescription.
1997 [15]
Kawaguchi et al 16 years 224 Single Center Patient and technique survival.
1997 [16]
Fenton et al 5 years 2,841 Multicenter Canadian dialysis population, derived from registry data. Patient survival.
1997 [3]
Stoke Study 7 years 303 Single Center Patient and technique survival. Detailed data on nutrition, solute clearance
and membrane function.1998

















Maiorca et al 56.2 20.2% 20–25% 50% 70%a
1991 [2]
Rotellar et al 47 18% not stated 60% 64%
1991 [8]
Lupo et al 58.4 13% 31% 48% 58.5%
1994 [10]
Maiorca et al 62 13% 22–25% 60%a 72%
1996 [13]
Kawaguchi et al 47.6 13.8% not stated 50% 55%
1997 [16]
Fenton et al 63b 31.9% 43.4% 35% n/a
1997 [3]
Stoke Study 58.8 14.8% 32% 55% 70%
1998
a Data adjusted for risk factors
b Estimated from published distribution
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Stoke study design
All patients new to peritoneal dialysis at this center from
the beginning of 1990 were entered into the study. While
they remained on PD, they had assessments as outpatients
for comorbidity, dialysis adequacy, dietary protein and
calorie intake, peritoneal membrane function, biochemis-
try, lipid profiles, weight and anthropometrics every six
months. Until the latter part of 1995 this was a purely
observational study. Subsequently, those patients with clin-
ical evidence of malnutrition (SGA of B or C) received a
25% increment in their delivered peritoneal dialysis dose.
For the present study the population was censored in
January 1998, at which point a policy decision was made to
increase the dialysis dose across the board to reach dialysis
adequacy targets (Kt/V 2.0 or creatinine clearance 60
liters/week). All patients were censored to allow overall
patient and technical survival to be calculated, as well as
survival according to treatment modality at the time of
death/censor. The clinical and dialysis records were exam-
ined to ascertain the mode of death.
Mode of death
Prior to assessment of the clinical records, six categories
describing the events at the time of death were identified.
These were: (1) sudden death, characterized by sudden
collapse, being found dead at home unexpectedly, cardio-
respiratory arrest in hospital or a cerebrovascular event
resulting in rapid decline and death within the next few
days; (2) debilitation, a death characterized by frequent
hospital admissions, always expected and often associated
with treatment withdrawal at the point at which the outlook
was considered hopeless; (3) sepsis, an uncontrolled infec-
tion at the time of death resulting in septic shock; (4)
peritonitis, active PD peritonitis at the time of death, or
requiring Tenckhoff catheter removal during the previous
14 days; (5) recent amputations, fulfilled if the patients had
undergone a recent amputation, or were still hospitalized
following amputation, even if the duration was several
months; and (6) non-compliance, in this context it was
defined as an overt inability or refusal to comply with
treatment. One or more of the above categories could be
identified as relevant in contributing to the mode of death
in each patient, but where more than one category was
fulfilled, one was identified as being the predominant
mode. Hospital records were examined by two independent
observers, and where a difference in categorization was
obtained, the evidence was re-examined in order to obtain
consensus.
Weight and mid-arm circumference
Actual body weight on the day of clinical assessment was
used. The mid-arm circumference (MAC) was measured by
one of a team of experienced renal dieticians, using a
standard technique [24]. Intra-observer error between die-
ticians was re-assessed every two months, and found to be
consistently within 2 mm (,1%).
Diet
Dietary protein (DPI) and calorie intake (DCI) were
assessed by an experienced renal dietician who was blinded
to the urea kinetic data, and who used a detailed dietary
interview to establish the protein and calorie intake at
home over the previous 24 hours. Data from this interview
were analyzed by a dietetic software package, Microdiet
(copyright University of Salford, 1983, 1988, Mark 7.10).
This method of assessing protein and calorie intake has
been carefully evaluated in our unit, and validated by an
independent dietician working with a different group of
CAPD patients and normal controls.
Peritoneal equilibration test
The peritoneal equilibration test (PET) was utilized to
measure peritoneal kinetics, and this was performed as
described previously [17, 20, 25]. Briefly, a standard four-
hour dwell period was used (first exchange of the day), with
a 2.27% glucose concentration-2 liter volume exchange.
Patients used their usual overnight dialysis regime, and
both the overnight and test drainage volumes were mea-
sured. Net ultrafiltration (UF) was calculated as the differ-
ence between the 2 liters of instilled dialysate and the
volume drained after the four hour dwell. The dialysate:
plasma creatinine ratio of creatinine at the completion of
the four-hour dwell period (D/PCr) was used as the estimate
of low molecular weight solute transfer. As glucose inter-
feres with the assay for creatinine in a linear fashion,
concentrations for both these solutes were measured at
four hours, and the true value for creatinine obtained by
subtracting the glucose concentration multiplied by a cor-
rection factor derived locally by our laboratory (0.47).
Using this method, the four-hour D/PCr is a highly repro-
ducible measure of low molecular weight solute transfer
across a wide range of values (0.45 to 0.9), in the short term
(3 months or less, provided there has been no clinical event
such as peritonitis or surgery), with a coefficient of varia-
tion of 3 to 5%. Normal ranges 6 95% confidence interval
(CI) for D/PCr were 0.635 6 0.25 and net ultrafiltration
498 6 409 ml.
Comorbid disease
The approach to identification of significant comorbid
disease has been described previously, where it has been
shown to predict patient survival [18, 19]. The following
categories of active comorbid disease were: (1) malignancy,
defined as an active, non-cutaneous disease, such as my-
eloma and breast cancer; (2) ischemic heart disease, as
evidenced by previous myocardial infarction, angina pecto-
ris, positive coronary angiography or the presence of isch-
emic changes on the resting ECG; (3) peripheral vascular
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disease, to include distal aortic, lower limb and cerebrovas-
cular disease; (4) left ventricular dysfunction, defined as
clinical evidence of pulmonary edema, not attributable to
errors in fluid balance, and/or left ventricular dysfunction
on echocardiography; (5) diabetes mellitus (Type 1 and
Type 2); (6) systemic collagen vascular disease, such as
vasculitis, rheumatoid arthritis and systemic sclerosis; (7)
other significant pathology, for example, chronic obstruc-
tive airways disease, cirrhosis.
Dialysis dose
The dialysis dose (Kt/V) was assessed by calculating the
weekly Kt/Vurea from the 24-hour urinary and dialysate
clearances, by direct measurement of urea in urine and
each dialysate exchange. The volume of distribution for
urea was calculated as 58% of the body wt. Results are
expressed as the total weekly Kt/Vurea (peritoneal and renal
components), or for the residual renal function (RRF)
alone.
Protein nitrogen appearance
Protein nitrogen appearance (PNA) was calculated using
the equation derived from detailed nitrogen balance stud-
ies in CAPD patients [26]:
PNA ~g/day! 5 @0.261 z UA ~mmol/day!# 1 13
1 TPL ~g/day!
where UA is the total (urine plus dialysate) urea appear-
ance and TPL is the total (urine plus dialysate) protein loss
over 24 hours.
Analytical methods
Plasma and dialysate concentrations of urea, creatinine
and glucose were determined on an automated discrete
random access analyzer (DAX 72; Bayer Instruments,
Basingstoke, UK). Plasma triglycerides were measured by
enzymatic determination, using the GPO-POD reagent.
Urine and dialysate total protein estimations were made
using the biuret method. Plasma albumin levels were
measured using the Bromocresol green method.
Statistical analysis
Univariate analysis of actuarial survival following entry
to the study was performed using the Kaplan-Meier
method, and the log-rank test was used to compare survival
between subgroups. Longitudinal comparisons in clinical
parameters were made using paired or unpaired t-tests
where appropriate. The x2 test was used to compare the
distribution of mode of death according to different comor-
bid conditions. Multivariate analysis of solute clearance,
plasma albumin and peritoneal solute transport, and their
prediction of patient and technique survival (excluding
deaths) were performed using Cox proportional hazard
modeling.
PATIENT SURVIVAL AND MODE OF DEATH ON
PERITONEAL DIALYSIS
Patient survival
A comparison of the five-year survival rates for those
studies that did not apply patient selection are summarized
in Table 2. While the differences are apparent, these are
not large and can be explained by the variability in the case
Fig. 1. Actuarial survival of the whole patient
population (N 5 303), representing all patients
treated with peritoneal dialysis since 1990. The
actual numbers of patients alive at each 12
month time point are shown.
Davies et al: The patient on long-term peritoneal dialysis2210
mix, as indicated by the mean age and the proportion of
patients treated who had diabetes mellitus and cardiovas-
cular disease. The actuarial patient survival curve, and
numbers of patients at risk as defined for the Stoke Study,
in which 98% of patients were white Caucasian and 58%
were male, are shown in more detail in Figure 1.
Cause and mode of death in peritoneal dialysis patients
The majority of studies in long-term PD patients do not
provide detailed information as to how these patients die,
and yet if we are to understand what really happens to these
individuals, this information is vital. The best data describ-
ing the cause of death come from the Italian studies, in
which sudden or cardiovascular deaths account for 45 to
47%, cachexia and malignancy for 23 to 25%, sepsis for 12
to 13%, and miscellaneous causes comprising the rest [2,
10, 13].
In the analysis of our own data, we chose to describe the
mode of death, rather than ascribe a specific cause. The
purpose of this approach was to define as clearly as possible
those factors contributing to death, as well as the influence
of the current treatment modality. Of 106 consecutive
deaths, detailed information was available from the hospi-
tal notes or dialysis records in 93 (88%) of the events
surrounding death. Of these, the independent observers
agreed on categorization of contributory factors in 92% of
cases. Of the total number of deaths, 58% occurred when
the patient was on PD and 42% after transfer to hemodi-
alysis or transplantation. The contribution of each category
describing the mode of death, that is, whether it was the
predominant or a contributory factor, is summarized in
Table 3. It can be seen that sudden death and debilitation
are by far the two most important categories, and that the
proportions of patients still on PD verses alternative treat-
ment modalities are very similar, and reflect the whole
population. While sepsis and peritonitis were important
contributors to the mode of death, it was much less
common for them to be the predominant mode. These
observations are certainly compatible with the ascribed
causes of death in the literature (see above), although the
role of debilitation appears to be important, and this is of
course not specific to the cause. When the predominant
mode of death was analyzed according to the pre-existing
comorbid disease states (Table 4), it can be seen that there
is a spectrum of balance between sudden and debilitated
death. The proportion is approximately equal for those
with ischemic heart disease, vascular disease and diabetes,
with increasing debilitation seen in those with left ventric-
ular dysfunction, and the majority of those with cancer
being debilitated. Sepsis and peritonitis were more likely to
be the predominant factors in patients with collagen vas-
cular disease or other pathologies. Debilitated patients
tended to die earlier, the median time to death being 15
months compared to 24 months if death was sudden, but
this was not significant (P 5 0.27).
Technique survival
Overall technique failure rates seen in the cohort studies
are summarized in Table 2. While at first sight these rates
appear to be quite good, it must be remembered that these
exclude PD patients whose death may have been a conse-
quence of a “failure” of the technique. Furthermore, in the
case of comparative studies with hemodialysis, PD tech-
nique failure has been found consistently to be worse, a
difference that gets progressively greater with time on
treatment [2, 13]. In the study with the longest follow-up,
18% of the PD patients had switched modality as compared
to 2.8% of the hemodialysis patients [13].
The reasons for technique failure are summarized in
Table 5. It is clear that recurrent or severe peritonitis
continues to be an important cause, although improve-
ments in technique survival have been observed in some
studies with time, primarily due to a reduction of this
problem. Multiple or severe peritonitis events are probably
an important risk factor for the development of sclerosing
peritonitis [27]. The development of sclerosing peritonitis
is, however, best correlated with time on treatment. In-
creasing, although anecdotal, evidence in centers having
significant experience with long-term PD patients suggest
that while sclerosing peritonitis may be precipitated by an
infectious episode, its occurrence does not necessarily
correlate with its severity or with the patient’s previous













Sudden 62% 41% 42%
Debilitation 57% 45% 53%
Sepsis 50% 6.8% 19.3%
Peritonitis 50% 4.5% 21.6%
Recent amputations — 0% 3.4%
Non-compliance 50% 2.2% 3.4%
Mean 58%






Ischemic heart disease 38 52% 48%
Peripheral vascular disease 26 48% 52%
Diabetes mellitus 18 46% 53%
Left ventricular dysfunction 23 40% 55%
Collagen vascular disease 7 28% 57%
Other 14 38% 30%
Malignancy 17 21% 79%a
A total of 15% of patients with collagen vascular disease died of
peritonitis. In patients with “other” pathologies, sepsis accounted for 15%
of deaths and peritonitis 10%.
a Proportionately more patients debilitated, x2, P , 0.04
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infection history. These data suggest that other factors,
such as continuous exposure to unphysiological solutions
and/or possible genetic predisposition, may be important in
its etiology.
Longevity of treatment is also thought to be a risk factor,
but it can occur early in treatment, and cases are so
sporadic that none of the cohort studies reviewed here is
able to define this problem more clearly [27, 28].
In our own patient cohort, two cases have occurred in
which severe staphylococcal infections were the apparent
precipitating factor.
Ultrafiltration failure, although not always clearly differ-
entiated from solute clearance, appears to be the next most
important treatment-related cause for drop-out. Defini-
tions of ultrafiltration vary, and usually combine clinical
features such as an inability to maintain dry weight without
excessive utilization of hypertonic glucose solutions, with a
membrane function definition as established by PET or the
equivalent, often related to high solute transport [17, 28,
29]. There is increasing evidence that ultrafiltration failure
increases with time on PD [20, 30], such that it becomes the
predominant cause of technique failure in long-term pa-
tients [16].
We were interested to see how the type of technique
failure related to patient survival. When actuarial survival
curves are plotted according to treatment modality at death
or censor (Fig. 2), it can be seen that survival in the
transplanted patients was 84% at five years, which is
significantly better (P , 0.001) than the survival of those on
PD (50% at five years) and all other causes of technical
failure. Five-year actuarial survival for patients who
switched therapies were less good (32% for peritonitis, P 5
0.005; 38% for ultrafiltration failure, P 5 0.3) when com-
pared to those who remained on PD. The group that fared
worst, despite a treatment switch, were those who failed to
thrive or cope with PD (P , 0.002 compared to all other
groups). It would appear, therefore, that if PD is stopped
for multiple peritonitis or failure to thrive, this is a marker
Fig. 2. Actuarial survival of patients according
to the treatment modality (Group 1 is PD;
Group 2 is transplant; Groups 3 to 5 are on
hemodialysis at the time of death or censor
(January 1998). Survival in Group 2 was better
than for all other groups, P , 0.001 (Log-rank
test). Survival for patients remaining on PD was
also favorable when compared to all forms of
technical failure: Group 3 (multiple peritonitis),
P , 0.05; Group 4 (ultrafiltration failure), P 5
0.32 and Group 5 (failure to thrive or manage),
P , 0.007.
Table 5. A comparison of causes of technical failure in long-term PD studies
Source









Maiorca et al 48.8% 22.1% 10.9% 11.9% 13%
1991 [2]
Lupo et al 29% 16.4% 8.5% 13.3% 11%
1994 [10]
Maiorca et al 37% 9% 9% 4% 13% 37%
1996 [13]
Kawaguchi et al 13.6% 23.5% — 2.3% 44% 15.2%
1997 [16]
Stoke Study 54% 27% — 2% — 17%
1998
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for poor survival despite the treatment transfer. Prevention
of treatment drop-out, with the exception of transplanta-
tion, must remain a continuing goal for the future.
Prediction of patient survival and technical failure
All of the studies under review agree that age and
comorbid disease are important determinants of long-term
patient survival on PD. Shorter-term cohort studies, most
notably the CANUSA study, have identified a number of
additional risk factors that predict poor clinical outcome in
PD patients [5, 9]. More recently, we have extended these
observations to patients remaining up to five years on
treatment, confirming the importance of residual renal
function as the most important treatment related factor [7].
We also found high peritoneal solute transport to predict
death independently on multivariate analysis. Similar find-
ings have been reported from Sweden [31] and continuing
analysis of the CANUSA study data has shown that in the
short-term, high solute transport predicts technique failure
[32]. In view of this relationship to technique failure, we
have repeated this analysis on the Stoke cohort for the
purposes of this review. Using multiple Cox regression
(Table 6), patient survival is predicted by Kt/V (residual
renal function being responsible for the inter-patient vari-
ability), plasma albumin and solute transport characteris-
tics measured six months into treatment. In contrast,
technique failure (excluding deaths on PD) was predicted
by high solute transport alone. It therefore appears that
high peritoneal solute transport characteristics early in the
course of treatment predict both reduced patient survival
and technical failure in patients observed for up to seven
years.
Longitudinal changes in clinical parameters
In general, studies that have performed detailed longitu-
dinal analyses of clinical parameters such as solute clear-
ance, nutrition and peritoneal function tend to be smaller
with respect to patient numbers, and frequently describe
selected sub-groups of patients [9, 11, 12, 33, 34]. One of
the strengths of the Stoke Study is that this detail exists for
an unselected population of sufficient size and length of
follow-up to allow us to begin to answer the question: what
really happens to these patients?
Solute clearance
One of the principle achievements of CANUSA was to
draw attention to the considerable consequences of loss in
residual renal function in PD patients, in particular its
effect on solute clearance [5]. Other studies have indicated
the value of prolonged residual renal function in long-term
PD patients to their survival [9, 33, 34]. One of the positive
features of peritoneal dialysis as a treatment modality is
that it tends to permit RRF to persist [35], and this is
particularly the case for the long-term group in the Stoke
patients, a proportion of whom (25%) still had some
function at five years. The longitudinal changes in total
urea clearance (Kt/Vurea) and residual renal function
(RRF) are shown in Figure 3, along with the actual number
of data points collected at each time point. Data are shown
both for the whole population regardless of final treatment
outcome, and for a subpopulation of long-term survivors on
PD (N 5 25). It can be seen that the loss in RRF is entirely
responsible for the drop in total Kt/Vurea, with an early
exponential phase during the first 18 months, a time when
most patients are experiencing a graded loss in their renal
function. This is followed by a more prolonged linear phase
Fig. 3. The longitudinal changes in urea clearance are shown for the
whole population (solid lines) and for the subgroup of long-term survivors
on PD, N 5 25, (dashed lines). Data are mean 6 SE. The initial clearances
are significantly greater (*P , 0.02) compared to later measurements, due
to the decline in residual renal function. In the medium term residual
renal function is relatively well maintained in the long-term patients,
(#P , 0.05). Net PD clearances are also shown (diamonds) for the whole
population.
Table 6. Cox proportional hazard models predicting patient death and technical failure by Kt/V, plasma albumin and peritoneal solute transport
Treatment
variable




(95% CI) P value
Relative risk
(95% CI) P value
Total weekly Kt/Vurea 0.48 (0.28–0.86) 0.016 0.86 (0.44–1.67) 0.65 Decrease per weekly unit
Plasma albumin 0.95 (0.9–1.02) 0.057 1.07 (0.97–1.18) 0.13 Decrease per g/liter
Solute transport 1.49 (1.04–2.12) 0.025 1.54 (1.06–2.24) 0.02 Increase per 0.1 unit in D/P ratio
(D/PCr at 4 hr)
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beyond two years that is still apparent at five years. The use
of mean values to represent RRF in this latter phase is
somewhat misleading, as the majority of patients are then
anuric, so that the continued decline is confined to a small
proportion only. It can be seen that RRF is relatively well
preserved in the long-term survivors.
Nutritional status
The longitudinal evolution of the nutritional parameters
over five years observed in the Stoke Study again support
and extend those made by CANUSA [36]. Changes in
weight and MAC are shown in Figure 4. During the first 12
months of treatment there was an increase both in weight
and MAC, implying increase in dry weight, both for the
whole population, and for those remaining on PD for five
years. After 18 months there was a steady decline in weight
that was delayed in the long-term group, although this was
not statistically significant. The parallel drop in MAC was
significant, however, suggesting that these patients were
losing proportionately more dry body weight, and by impli-
cation may be becoming relatively fluid loaded. Again, the
long-term survivors appeared to maintain dry weight better,
and this was responsible for the apparent rise in MAC
beyond four years.
The longitudinal changes in PNA, DPI and DCI are
shown in Table 7. These parameters all show a similar
trend, suggesting that the highest protein and calorie intake
occurs at the beginning of time on PD, prior to the weight
gain, followed by a decline. The fall in PNA is very gradual,
and although there may be some mathematical coupling
with the Kt/Vurea, the drop is linear rather than exponen-
tial. DPI is much more variable between individuals, but
even this shows a significant decline by five years. DCI is
also variable, but there is a significant fall by two to two
years, after which the numbers become too small to dem-
onstrate further change. The changes in plasma triglycer-
ides with time in PD are shown in Table 7. There is an
increase during the first twelve months of treatment, after
which they remain stable, with a non-significant trend to
reducing after 42 months. These changes reflect those in
the weight and MAC.
There is therefore a very significant early improvement in
nutrition, with evidence of good dietary intake, increase in
dry body wt and plasma triglycerides. These observations
were also found in the selected population of long-term PD
patients reported by Faller and Lameire [11, 34], who, like
the long-term subpopulation in the present analysis, had a
relatively well maintained nutrition for several years. The
evidence, however, that poor nutrition remains or becomes
an increasing problem for the majority of patients is very
Fig. 4. Data for the whole population and
long-term subgroup are shown as for Figure 3.
Data are mean 6 SE. Weight measurements are
shown as square symbols and mid-arm
circumference (MAC) as circles. There is a
significant rise in weight and MAC during the
first year of treatment (*P , 0.02), following
which both decline, although this is only
significant for MAC (1P , 0.05). Both weight
and MAC are relatively well maintained in the
long-term group, which is responsible for the
late relative improvement in MAC.
Table 7. Longitudinal changes in clinical parameters during the first five years of peritoneal dialysis
Clinical
variable
Months on peritoneal dialysis
1 6 12 18 24 30 36 42 48 54 60
Number 286 219 169 117 90 71 47 37 31 26 25
PNA g/day 80.9 6 1.6 78.8 6 1.6 76.1 6 1.8 75.2 6 2.0 73.5 6 2.2a 74.5 6 3.0a 68.3 6 3.0b 68.6 6 3.4b 72.1 6 4.0b 66.6 6 3.3b 67.4 6 4.0b
DPI g/day 69 6 2.4 69.6 6 2.1 65.9 6 2.5 66 6 2.8 62.5 6 2.5 69 6 3.4 64.5 6 4.7 68 6 5.9 66.4 6 3.8 60.4 6 5.2a 50.2 6 11.4a
DCI cal/day 1701 6 51 1699 6 54 1642 6 58 1648 6 56 1509 6 56 1531 6 65a 1656 6 97a 1773 6 137 1628 6 97 1771 6 90 1473 6 112
UF vol. ml 441 6 15 444 6 17 461 6 44 395 6 20 395 6 28 425 6 25 360 6 37a 391 6 37a 454 6 51 405 6 39 367 6 53a
Triglycerides 2.06 6 0.08 2.43 6 0.15 2.85 6 0.24a 2.62 6 0.18a 2.82 6 0.27b 3.1 6 0.46b 2.7 6 0.38a 2.51 6 0.24a 2.37 6 0.28a 2.25 6 0.38 2.33 6 0.37
mmol/liter
Abbreviations are: PNA, protein nitrogen appearance; DPI, dietary protein intake; DCI, dietary caloric intake; UF vol, ultrafiltration volume obtained
from net drainage on Peritoneal Equilibration Test.
a Different to baseline, P , 0.05
b Different to baseline, P , 0.02
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strong. Loss of dry body wt begins to occur after two years;
there is a downward trend in protein nitrogen appearance
and estimates of dietary intake, and this is despite a steady
loss of patients who die in a debilitated state. It is not
simply due to a progressive loss of well-nourished patients
to transplantation, as these patients tend to be younger and
less overweight than their counterparts.
Peritoneal membrane function
There is now increasing evidence from cross sectional
studies, selected and unselected longitudinal cohort studies
that peritoneal solute transport increases with time on PD,
at least for a proportion of patients [7, 12, 20, 23, 37].
Longitudinal changes in peritoneal solute transport (Fig. 5)
demonstrate that for the whole group, after an initial early
increase in D/PCr, the membrane function would appear to
be stable for up to three years, after which there is a
significant increase in transport associated with a reduction
in the peritoneal ultrafiltration capacity (Tables 6 and 7).
The membrane function in the long-term PD group is
different, in that solute transport rates are significantly
lower between 18 and 30 months of treatment, before the
subsequent rise.
The period of peritoneal membrane stability between 12
and 42 months may be more apparent than real. As
discussed above, high solute transport early in treatment is
associated with increased treatment dropout due to death
and technical failure. There is, therefore, a systematic loss
of patients with high solute transport occurring throughout
this period. Added to this is the fact that patients with
prolonged survival on PD had lower transport rates during
this time period, perhaps contributing to better fluid bal-
ance at this stage of treatment, which will further distort the
apparent mean values for the whole group. Indirect evi-
dence that low solute transport in long-term survivors may
be protective is the relatively well maintained plasma
albumin is these patients during the same time interval
(Fig. 6). It is equally tempting to speculate that solute
transport was relatively stable in this group of patients due
to their persisting RRF, resulting in a lesser requirement
for hypertonic glucose exchanges. Finally, long-term sur-
vival appears to be associated with peritoneal solute trans-
port stability, typically with a D/PCr ratio in the region of
0.68 at four hours [7, 12, 14].
The gradual decline in plasma albumin (Fig. 6) with time
on PD is clearly a matter for concern. Low plasma albumin
has been repeatedly linked to poor clinical outcome [5, 6,
21, 38], and predicts worsening cardiovascular morbidity
[39]. While it reflects a combination of poor prognostic
features, namely comorbidity [6, 18, 33], high solute trans-
port (due to both increased protein clearances and im-
paired ultrafiltration) and poor nutritional status, which of
these is the predominant cause for the decline in plasma
concentrations cannot be determined with certainty from
this study. There is certainly circumstantial evidence that
PD patients become progressively fluid loaded with time on
PD [40–42], supported here by the fall in MAC being more
pronounced than the drop in actual body weight. This is in
keeping with the view that because salt and water removal
are directly proportional to net ultrafiltration [43], that
peritoneal membrane function becomes critically important
to fluid balance once RRF has gone.
CONCLUSION
This review has attempted to describe in as much detail
as possible what actually happens to patients treated with
peritoneal dialysis over a period of several years. It must be
borne in mind that all the studies referred to here belong to
a period in the development of the treatment modality in
which few, if any, specific measures were taken to take
account for the loss in residual renal function. Conse-
quently, all these patients were progressively disadvantaged
in terms of their small solute clearances, and potentially
their salt and water removal as well.
Fig. 5. Data for the whole population and long-term subgroup are shown
as for Figure 3. Solute transport increases with time on PD (*P , 0.05,
compared with 6 months duration). The long-term subgroup has a
significantly lower solute transport in the medium term (#P , 0.05).
Fig. 6. Data for the entire population and long-term subgroup are shown
as for Figure 3. There is a downward trend in the plasma albumin with
time, which reaches significance beyond 42 months (*P , 0.05). Plasma
albumin is relatively well preserved in the long-term group, as it is
significantly higher between 13 and 30 months of treatment (#P , 0.05).
Davies et al: The patient on long-term peritoneal dialysis 2215
In summarizing what actually happens to patients treated
for several years on PD it is possible to produce a synthesis
from the studies discussed. Those who do well have less
comorbid disease, have maintained residual renal function,
and proceed to transplantation. Those who die usually
suffer either a sudden cardiac death or a slower debilitation
period to their eventual death, and it is easy to see how
progressive malnutrition, under-dialysis, and poor salt and
water handling will contribute to these outcomes. Evidence
for an important role for peritoneal membrane function is
also increasingly compelling. High solute transport predicts
death and technical failure, and increases with time on
treatment. Once the patient is anuric, as is the case for the
vast majority of long-term PD patients, high membrane
solute transport will influence ultrafiltration and thus salt
and water balance. It must be hoped that with strategies
designed to preserve and optimize peritoneal membrane
function, the future for long-term peritoneal dialysis can be
assured.
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